Sort   by:  
 Page size 
UnknownRandomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Not available
S-EPMC5569675 | biostudies-literature
MetabolomicsGut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy
Numerous studies found intestinal microbiota alterations which are thought to affect the development of various diseases through the production of gut-derived metabolites. However, the specific metabolites and their pathophysiological contribution to cardiac hypertrophy or heart failure progression ...
2021-12-08 | MTBLS3174 | MetaboLights
GenomicsGenome-Wide Association Studies in Upper Gastrointestinal Cancers (Asian)

This project aims to conduct genome-wide association studies (GWAS) in two anatomically different upper gastrointestinal (UGI) cancer sites in two populations with distinctly different disease rates and genetic profiles. One population has very high rates for both esophageal squamous cel...

phs000361.v1.p1 | EGA
ProteomicsInsulin Signaling Regulates Longevity Through Protein Phosphorylation in Caenorhabditis elegans
Insulin/IGF-1 Signaling (IIS) is known to constrain longevity by inhibiting the transcription factor FOXO. How phosphorylation mediated by IIS kinases regulates lifespan beyond FOXO remains unclear. Here, we profile IIS-dependent phosphorylation changes in a large-scale quantitative phosphoproteomic...
ORGANISM(S): Caenorhabditis Elegans 
2021-06-10 | PXD020440 |
MetabolomicsMetabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

BACKGROUND: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great cl...

2022-01-13 | MTBLS239 | MetaboLights
UnknownDe novo mutations across 1,465 diverse genomes reveal mutational insights and reductions in the Amish founder population.
Not available
S-EPMC7007577 | biostudies-literature
Sort   by:  
 Page size